%0 Journal Article
%T Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
%A Arthur Vegh
%A Debora Williams-Herman
%A Henrike Feuersenger
%A Inmaculada Martinez-Saguer
%A James W. Baker
%A Jonathan A. Bernstein
%A Jonathan Edelman
%A Marc A. Riedl
%A Markus Magerl
%A Mikhail Rojavin
%A Paula Busse
%A Ralph Shapiro
%A Thomas Machnig
%A Timothy Craig
%A William Lumry
%J Archive of "Allergy & Rhinology".
%D 2017
%R 10.2500/ar.2017.8.0192
%X The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis
%K Berinert
%K hereditary angioedema
%K long-term prophylaxis
%K plasma-derived C1-inhibitor
%K registry
%K safety
%K efficacy
%K thromboembolic events
%K self-administration
%K dosing
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380447/